Published in:JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Language:
English
DOI:
10.1111/ddg.14501
ISSN:
1610-0387;
1610-0379
Origination:
Footnote:
Description:
<jats:title>Summary</jats:title><jats:sec><jats:title>Background and objectives</jats:title><jats:p>There is a lack of data regarding the situation of melanoma patients receiving systemic therapies in their last months of life.</jats:p></jats:sec><jats:sec><jats:title>Patients and methods</jats:title><jats:p>All melanoma patients who died in 2016 or 2017 and who had been treated by systemic therapies within the last three months of life were retrospectively analyzed. The study was conducted within the Committee “supportive therapy” of the Work Group Dermatological Oncology (ADO).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>193 patients from four dermato‐oncological centers were included. More than 60 % of the patients had ECOG ≥ 2 and most of them received immune checkpoint inhibitors (ICI) or targeted therapies (TT). 41 patients benefited from the last therapy in terms of radiological and laboratory findings or state of health. Although ECOG was worse in the TT cohort compared to the ICI group, the proportion of patients benefiting from the last therapy with TT was significantly higher and TT therapy could be carried out more often on an outpatient basis.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This study indicates that there is a tendency towards an overtreatment at the end of life. Nevertheless, TT might be a reasonable therapeutic option for advanced <jats:italic>BRAF</jats:italic> mutant melanoma, even in highly palliative situations.</jats:p></jats:sec>